New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
07:13 EDTDCTHDelcath Systems announces reimbursement for Chemostat in Chermany
Delcath Systems announced that the Institut für das Entgeltsystem im Krankenhaus, the German federal reimbursement agency, has established a reimbursement pathway for the treatment of patients with liver metastases with the Delcath Hepatic CHEMOSAT Delivery System for melphalan hydrochloride. The Value 4 status given to the CHEMOSAT procedure, while not mandating reimbursement, allows participating cancer centers to negotiate reimbursement coverage for the CHEMOSAT procedure with all insurers serving their region. Under the NUB scheme, reimbursement pathways will potentially be available for treatment with CHEMOSAT regardless of primary cancer origin.
News For DCTH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
08:07 EDTDCTHDelcath Systems begins enrollment for Phase trial of Melphalan/IDS
Delcath Systems' intrahepatic cholangiocarcinoma study cohort of its expanded Global Phase 2 Clinical Trial Program of Melphalan/HDS for use in the treatment of patients with unresectable hepatocellular carcinoma - primary liver cancer, or HCC - has opened for patient enrollment. The ICC study will be conducted at the same hospitals in Europe participating in the company's Phase 2 HCC trial, and ICC enrollment is now open at Goethe University Hospital in Frankfurt, the Medical School Hannover and Jena University Hospital. Additional centers in Germany and the U.K. are expected to open for enrollment in the coming weeks.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use